Physician profile
Carl D Morrison
NPI 1932142379
$19,792.11
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.02 · 2020: $15K · 2021: $2,320 · 2022: $2,077.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13,125.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,377.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $2,188.61 | 2020 | |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2022 | |
| Foundation Medicine, INC. | $81.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.